{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060715","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.353369+00:00","generated_at":"2026-06-02T01:09:22.677592+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia Q1 net loss widens to $40.9M; YUTREPIA legal barriers removed","bullets":["Net loss $40.9M ($0.54/share) vs $11.7M ($0.18) in Q1 2023; revenue fell 33% to $3.0M on lower Treprostinil Injection sales.","Cash $157.9M after $100M gross proceeds from common stock private placement and RIFA fourth amendment in January 2024.","G&A expenses surged 160% to $20.2M, driven by $3.1M higher litigation costs and $5.9M personnel rise.","All legal barriers to FDA approval of YUTREPIA removed; awaiting ruling on preliminary injunction in new UTHR patent suit.","ASCENT study of YUTREPIA in PH-ILD enrolling; L606 liposomal treprostinil data to be presented at ATS 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060715","json":"https://secwatch.observer/filing/0001104659-24-060715.json","markdown":"https://secwatch.observer/filing/0001104659-24-060715.md","text":"https://secwatch.observer/filing/0001104659-24-060715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924060715/0001104659-24-060715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924060715/tm2414358d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:09:22.677592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}